Pestronk Lab

Research interests: Neuromuscular disorders

Clinical interests: Clinical neurology, neuromuscular disease, neuroimmunology, glycolipids, proteoglycans, aging and the nervous system, history of neurology, myopathy, neuropathy, weakness, myasthenia, muscle, nerve, numbness, sensory loss, pain, fatigue, muscular dystrophy, neuro muscular.

Learn more on the Neuromuscular Disease Center website »

Principal investigator

Alan Pestronk, MD

Professor of Neurology
Adult, Neuromuscular Medicine
Director, Neuromuscular Clinical Laboratory

• Phone: 314-362-6981

  Pestronk lab

 

Top areas of adult care: myopathy, neuropathy, myasthenia gravis

Recent publications

• Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease
  December 1, 2024
  Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe diseaseon behalf of the PROPEL Study Group, Dec 2024, In: Journal of Patient-Reported Outcomes. 8, 1, 132.Research output: Contribution to journal › Article › peer-review
• Seeding-competent TDP-43 persists in human patient and mouse muscle
  November 27, 2024
  Seeding-competent TDP-43 persists in human patient and mouse muscleLynch, E. M., Pittman, S., Daw, J., Ikenaga, C., Chen, S., Dhavale, D. D., Jackrel, M. E., Ayala, Y. M., Kotzbauer, P., Ly, C. V., Pestronk, A., Lloyd, T. E. & Weihl, C. C., Nov 27 2024, In: Science translational medicine. 16, 775, eadp5730.Research output: Contribution to journal › Article › peer-review
• Ophthalmoparesis as an unusual manifestation of anti-3‑hydroxy-3-methyl-glutaryl-coenzyme A reductase antibody-associated myopathies
  September 1, 2024
  Ophthalmoparesis as an unusual manifestation of anti-3‑hydroxy-3-methyl-glutaryl-coenzyme A reductase antibody-associated myopathiesPutko, B., Pestronk, A., Van Stavern, G. P., Phan, C. L., Beecher, G. & Liewluck, T., Sep 2024, In: Neuromuscular Disorders. 42, p. 1-4 4 p.Research output: Contribution to journal › Article › peer-review
• Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
  May 1, 2024
  Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trialTawil, R., Wagner, K. R., Hamel, J. I., Leung, D. G., Statland, J. M., Wang, L. H., Genge, A., Sacconi, S., Lochmüller, H., Reyes-Leiva, D., Diaz-Manera, J., Alonso-Perez, J., Muelas, N., Vilchez, J. J., Pestronk, A., Gibson, S., Goyal, N. A., Hayward, L. J., Johnson, N. & LoRusso, S. & 19 others, Freimer, M., Shieh, P. B., Subramony, S. H., van Engelen, B., Kools, J., Leinhard, O. D., Widholm, P., Morabito, C., Moxham, C. M., Cadavid, D., Mellion, M. L., Odueyungbo, A., Tracewell, W. […]
• Biallelic variants in COQ7 cause distal hereditary motor neuropathy with upper motor neuron signs
  October 1, 2023
  Biallelic variants in COQ7 cause distal hereditary motor neuropathy with upper motor neuron signsRebelo, A. P., Tomaselli, P. J., Medina, J., Wang, Y., Dohrn, M. F., Nyvltova, E., Danzi, M. C., Garrett, M., Smith, S. E., Pestronk, A., Li, C., Ruiz, A., Jacobs, E., Feely, S. M. E., França, M. C., Gomes, M. V., Santos, D. F., Kumar, S., Lombard, D. B. & Saporta, M. & 6 others, Hekimi, S., Barrientos, A., Weihl, C., Shy, M. E., Marques, W. & Zuchner, S., Oct 1 2023, In: Brain. 146, 10, p. 4191-4199 9 p.Research output: Contribution to journal › Article › […]